Guerbet Future Growth

Future criteria checks 3/6

Guerbet is forecast to grow earnings and revenue by 18.3% and 6.1% per annum respectively. EPS is expected to grow by 18.1% per annum. Return on equity is forecast to be 9.6% in 3 years.

Key information

18.3%

Earnings growth rate

18.1%

EPS growth rate

Medical Equipment earnings growth	22.6%
Revenue growth rate	6.1%
Future return on equity	9.6%
Analyst coverage	Good
Last updated	31 Oct 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

LSE:0ELV - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	972	48	56	135	4
12/31/2025	920	38	34	117	6
12/31/2024	856	28	13	103	7
6/30/2024	841	33	18	70	N/A
3/31/2024	818	28	-4	49	N/A
12/31/2023	796	24	-26	27	N/A
9/30/2023	785	-9	-38	15	N/A
6/30/2023	775	-42	-51	3	N/A
3/31/2023	772	-42	-35	17	N/A
12/31/2022	769	-41	-19	30	N/A
9/30/2022	757	-14	-1	49	N/A
6/30/2022	746	13	17	67	N/A
3/31/2022	741	23	43	92	N/A
12/31/2021	736	33	68	116	N/A
9/30/2021	724	33	59	109	N/A
6/30/2021	712	33	51	103	N/A
3/31/2021	715	26	56	112	N/A
12/31/2020	717	18	62	120	N/A
9/30/2020	751	22	86	142	N/A
6/30/2020	785	26	110	163	N/A
3/31/2020	802	32	91	147	N/A
12/31/2019	819	37	72	131	N/A
9/30/2019	813	40	52	110	N/A
6/30/2019	807	43	32	88	N/A
3/31/2019	801	45	33	83	N/A
12/31/2018	795	47	33	77	N/A
9/30/2018	793	46	29	68	N/A
6/30/2018	790	46	24	59	N/A
3/31/2018	800	46	N/A	58	N/A
12/31/2017	809	46	N/A	56	N/A
9/30/2017	807	43	N/A	46	N/A
6/30/2017	805	40	N/A	35	N/A
3/31/2017	791	34	N/A	37	N/A
12/31/2016	776	29	N/A	39	N/A
9/30/2016	709	30	N/A	46	N/A
6/30/2016	642	31	N/A	54	N/A
3/31/2016	566	35	N/A	60	N/A
12/31/2015	490	39	N/A	66	N/A
9/30/2015	462	37	N/A	67	N/A
6/30/2015	435	35	N/A	69	N/A
3/31/2015	422	30	N/A	64	N/A
12/31/2014	410	26	N/A	60	N/A
9/30/2014	405	24	N/A	59	N/A
6/30/2014	400	23	N/A	57	N/A
3/31/2014	395	22	N/A	58	N/A
12/31/2013	391	20	N/A	59	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 0ELV's forecast earnings growth (18.3% per year) is above the savings rate (2.1%).

Earnings vs Market: 0ELV's earnings (18.3% per year) are forecast to grow faster than the UK market (14.8% per year).

High Growth Earnings: 0ELV's earnings are forecast to grow, but not significantly.

Revenue vs Market: 0ELV's revenue (6.1% per year) is forecast to grow faster than the UK market (3.6% per year).

High Growth Revenue: 0ELV's revenue (6.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 0ELV's Return on Equity is forecast to be low in 3 years time (9.6%).

Guerbet Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Guerbet SA Provides Earnings Guidance for the Year 2024

Guerbet SA Confirms Revenue Guidance for the Year of 2022

Guerbet Sa Provides Revenue Guidance for 2022

Guerbet Provides Group Earnings Guidance for the Year 2021

Recent updates

Guerbet SA to Report First Half, 2025 Results on Sep 25, 2025

Guerbet SA to Report Fiscal Year 2024 Results on Mar 27, 2025

Investor sentiment deteriorates as stock falls 16%

New major risk - Financial position

Guerbet SA Announces Board Changes

Guerbet SA Provides Earnings Guidance for the Year 2024

New major risk - Financial position

Dividend of €0.50 announced

Guerbet SA, Annual General Meeting, May 24, 2024

First half 2023 earnings released: EPS: €0.16 (vs €0.26 in 1H 2022)

Guerbet Announces Management Appointments

Applied Radiology and Guerbet Launch 'Elucirem (Gadopiclenol) Injection

Full year 2022 earnings released: €3.25 loss per share (vs €2.59 profit in FY 2021)

Guerbet Releases First Production Batch of Elucirem (Gadopiclenol) Injection, a Novel New Macrocyclic GBCA for Use in Contrast-Enhanced Magnetic Resonance Imaging

Guerbet SA, Annual General Meeting, May 26, 2023

First half 2022 earnings released: EPS: €0.26 (vs €1.86 in 1H 2021)

Guerbet Announces U.S. Food and Drug Administration (FDA) Approval of Elucirem (Gadopiclenol)

Guerbet SA Confirms Revenue Guidance for the Year of 2022

Upcoming dividend of €0.85 per share

Guerbet Sa Provides Revenue Guidance for 2022

Guerbet Announces Appointment of Charlotte Bamière, General Counsel, to the Executive Committee

Guerbet Recently Submitted New Drug Application to the U.S. Food and Drug Administration

Full year 2021 earnings released

First half 2021 earnings released

Guerbet Provides Group Earnings Guidance for the Year 2021

Upcoming dividend of €0.70 per share

Full year 2020 earnings released

New 90-day low: €31.00

Guerbet SA to Report Fiscal Year 2020 Results on Mar 24, 2021

Guerbet SA, Annual General Meeting, May 28, 2021

New 90-day high: €35.40

Guerbet SA Receives Us Food and Drug Administration Approval for the Commercial Sale of the Optiray Imaging Bulk Package (IBP)

New 90-day high: €31.85

First half earnings released

Med Xl Inc acquired Pharmaceutical site in Montreal from Guerbet SA (ENXTPA:GBT).

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies